Home

The Infectious Diseases Clinical Research Consortium (IDCRC) and Vaccine and Treatment Evaluation Units (VTEUs) work in tandem with the National Institute of Allergy and Infectious Diseases (NIAID) as a coordinated national and global network of scientific experts working to develop and test vaccines and other therapies to combat infectious diseases.

Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine

Nine IDCRC sites enrolled participants in the the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273. An independent data and safety monitoring board overseeing the trial reported that the candidate was safe and well-tolerated and noted a vaccine efficacy rate of 94.5%.

NIH News
COVID-19 Vaccine Appears Well-Tolerated and Effective in Developing Antibodies in Small Study of Older Adults

COVID-19 Prevention Network

The CoVPN was established by merging four existing NIAID-funded clinical trials networks: the HIV Vaccine Trials Network; the HIV Prevention Trials Network; the Infectious Diseases Clinical Research Consortium; and the AIDS Clinical Trials Group.

More about the CoVPN
COVID-19 Prevention Network launches two research studies evaluating monoclonal antibodies

About


The IDCRC works through a flexible, sustaining structure to advance new countermeasures and approaches to product development, implement efficient clinical study/trial designs, and support exceptional career development and mentoring of future leaders in infectious diseases clinical research. The consortium's collective experience and access to diverse populations give it the ability to evaluate new vaccines and therapies for infectious diseases.

IDCRC Active & Completed Studies
IDCRC Logo

SUPPORT OF CLINICAL RESEARCH FOR 2019 NOVEL CORONAVIRUS (SARS-COV-2) & DISEASE (COVID-19)


The novel coronavirus 2019-nCoV, SARS-CoV-2, pandemic continues to expand and the IDCRC is working with NIAID to conduct clinical research into the treatment and prevention of infections (COVID-19) caused by this virus. What we know about COVID-19 and SARS-CoV-2 is constantly changing. To stay up-to-date on the most current information about how the epidemic is impacting the world, we recommend that you visit the following websites for reliable and accurate information.

View Resources

IDCRC Leadership Group

Emory University School of Medicine

University of Maryland Baltimore

Baylor College of Medicine

Cincinnati Children’s Hospital Medical Center

FHI 360

Fred Hutch

University of Alabama School of Medicine

Johns Hopkins School of Medicine

Vanderbilt University Medical Center

University of Washington

IDCRC Vaccine & Treatment Evaluation Units (VTEUs)

IDCRC Concept Quick Stats

ICP Status

  • Approved: 14
  • Administratively Not Supported: 16
  • Revise & Resubmit: 6
  • Withdrawn: 6
  • EWG Liaisons: 2
  • Not Approved: 21
  • EWG Co-Chairs: 2
  • Resubmitted to ACTIV per DMID: 1

EWG Assignment

  • STI: 2
  • Respiratory: 8
  • Malaria/Topical Diseases: 2
  • COVID: 59
  • ESTIB: 2
  • PIPB: 2

ECP

  • Transitioned to IDCRC for Protocol Implementation: 4
  • In Protocol Development: 3
  • ECP Pending: 2
  • Hold: 1
  • Submitted to ACTIVE Mab Program per DMID: 1
  • Transitioned to Pediatric Working Group: 1
  • Transition to Phase III Vaccine Protocol Development: 1
  • Approved to move to CRS: 1
  • Merged into AIRS Protocol: 2
  • Under discussion with DMID/NIAID: 1
  • Protocol Transitioned to ACTT 2: 1
  • Full EWG Review: 1
  • Funded by NIAID via OBRRTR: 1